New Hampshire Medicaid Fee-for-Service Program Convenience Kits (Rx) Criteria

Approval Date: May 12, 2026

Medications

Brand Name	Generic Name	Strengths
Qutenza®	Capsaicin/Skin Cleanser	8%
Ciclodan®	Ciclopirox/Skin Cleanser No. 28	0.77%
Loprox®	Ciclopirox/Skin Cleanser No. 40	0.77%
Ciclodan®	Ciclopirox/Urea/Camphor/Menthol/ Eucalyptus	8%
ciclopirox	Ciclopirox/Urea/Camphor/Menthol/ Eucalyptus	8%
Clindacin® ETZ	Clindamycin phosphate/Skin Cleanser No. 19	1%
Clindacin® PAC	Clindamycin phosphate/Skin Cleanser No. 19	1%
Neuac®	Clindamycin/Benzoyl/Emollient No. 94	1.2(1)%/5%
Tovet®	Clobetasol/Emollient No. 65	0.05%
Clodan®	Clobetasol/Skin Cleanser No. 28	0.05%
Morgidox®	Doxycycline/Skin Cleanser No. 19	50 mg, 100 mg
Synalar®	Fluocinolone/Emollient No. 65	0.025%
Synalar® TS	Fluocinolone/Skin Cleanser No. 28	0.1%
Beser™	Fluticasone/Skin Cleanser No. 25	0.05%
lidocaine-hydrocortisone	Lidocaine/Hydrocortisone AC	3%/2.5%; 3%/0.5%
Rosadan®	Metronidazole/Skin Cleanser No. 23	0.75%
Neo-Synalar®	Neomycin/Fluocinolone/Emollient No. 65	0.5%/0.025%
Sumaxin CP®	Sulfacetamide/Sulfur/Skin Cleanser No. 23	10%/4%
Sumadan®	Sulfacetamide/Sulfur/Skin Cleanser No. 23	9%/4.5%

Criteria for Approval

1. Kit is being prescribed for the FDA (Food and Drug Administration)-approved indication for all active ingredients; **AND**
2. The patient has had an adequate trial of a product with the active ingredient(s); **OR**
3. The active ingredient(s) are on drug shortage; **AND**
4. Non-preferred drugs on the Preferred Drug List (PDL) require additional prior authorization (PA).

Proprietary & Confidential
© 2006–2026 Prime Therapeutics State Government Solutions LLC, a Prime Therapeutics LLC company

Criteria for Denial

Failure to meet criteria for approval.

Approval period: 12 months

Criteria for Renewal

Patient must continue to meet above criteria.

References

Available upon request.

Revision History

Reviewed by	Reason for Review	Date Approved
DUR Board	New	12/02/2021
Commissioner Designee	New	01/14/2022
DUR Board	Update	06/19/2023
Commissioner Designee	Approval	06/29/2023
DUR Board	Update	10/15/2024
Commissioner Designee	Approval	11/21/2024
DUR Board	Update	04/21/2026
Commissioner Designee	Approval	05/12/2026

© 2006–2026 Prime Therapeutics State Government Solutions LLC, a Prime Therapeutics LLC company